Premium
Malignant hepatic epithelioid hemangioendothelioma with high‐output heart failure: Successful management of heart failure with transcatheter arterial chemoembolization
Author(s) -
Hsu ChienYi,
Liu YaoChung,
Li ChungPin,
Huang PoHsun,
Lin ChinHsuan,
Chao Yee
Publication year - 2014
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12056
Subject(s) - medicine , heart failure , embolization , radiology , cardiology , decompensation , arterial embolization , transcatheter arterial chemoembolization , epithelioid hemangioendothelioma , vascular resistance , hemodynamics , hepatocellular carcinoma , immunohistochemistry
A 73‐year‐old woman was admitted to hospital because of progressive dyspnea on exertion. Computed tomography revealed a large hepatic tumor, which was proved to be a hepatic epithelioid hemangioendothelioma ( EHE ). Echocardiography demonstrated high cardiac output, for which the tumor was considered to be the leading cause. A transcatheter arterial chemoembolization ( TACE ) was performed sequentially at 1‐month intervals to reduce the size of the hepatic tumor, and this temporarily improved the patient's cardiac condition and quality of life. In this case, we successfully used TACE in the treatment of hepatic EHE with high‐output heart failure. TACE is a reasonable choice of treatment both for managing malignant hepatic tumors and resolving low systemic vascular resistance by embolization of the abnormal neoangiogenic vessels. Nevertheless, clinicians should be aware of the potential adverse effect of hepatic decompensation induced by TACE , especially when the tumor involvement is widespread and poorly preserved hepatic function is encountered.